Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population Valentina Cannone, MD, PhD, Alessia Buglioni, MD, S. Jeson Sangaralingham, MS, PhD, Christopher Scott, MS, Kent R. Bailey, PhD, Richard Rodeheffer, MD, Margaret M. Redfield, MD, Riccardo Sarzani, MD, PhD, John C. Burnett, MD Mayo Clinic Proceedings Volume 93, Issue 8, Pages 980-990 (August 2018) DOI: 10.1016/j.mayocp.2018.05.027 Copyright © 2018 Mayo Foundation for Medical Education and Research Terms and Conditions
Figure 1 Plasma aldosterone levels in individuals with hypertension (HTN) stratified by number of anti-HTN drugs taken. The horizontal line in the middle of each box indicates the median; lower box, Q1; upper box, Q3; and diamond, mean. The whiskers extend to 1.5 × the interquartile range (IQR) above and below the box (or the maximum or minimum values if there are no points outside of 1.5 × IQR from the box). The circles are outliers. Unadjusted P< .001. To convert aldosterone values to pmol/L, multiply by 27.74. Mayo Clinic Proceedings 2018 93, 980-990DOI: (10.1016/j.mayocp.2018.05.027) Copyright © 2018 Mayo Foundation for Medical Education and Research Terms and Conditions
Figure 2 Inverse relationship between plasma aldosterone and atrial natriuretic peptide (ANP) levels in participants with hypertension. Aldosterone is analyzed by tertiles and ANP as a continuous variable (mean [95% CI]). P = .007 adjusted for age, sex, body mass index, myocardial infarction, heart failure, atrial fibrillation, and glomerular filtration rate. Mayo Clinic Proceedings 2018 93, 980-990DOI: (10.1016/j.mayocp.2018.05.027) Copyright © 2018 Mayo Foundation for Medical Education and Research Terms and Conditions